| Literature DB >> 36013408 |
Dominik Németh1,2, Györgyi Pónyai1.
Abstract
The proportion of elderly in the general population is increasing. Ageing of the skin and immune system can modify the features of contact hypersensitivity (CH). The number of epidemiological studies according to the age-related features of CH is very limited. We aimed to analyse the clinical characteristics of CH in an elderly patient population. A total of 600 patients (patient age > 60 years old) were patch tested with the European Environmental Baseline Series (EEBS) and 440 of them with the Complementary Fragrance Series (CFS) at the same time according to the actual international methodological standards in the Allergy Outpatient Unit of Department of Dermatology, Venereology and Dermato-Oncology of Semmelweis University between 2015-2019. Out of 600 tested patients, 54.8% had at least one allergen positivity. Female predominance was observed (78.7%). The most common diagnosis was contact dermatitis (63.7%), followed by psoriasis (6.2%). Most of the cases (58.0%) were found in the age group of 60-69. The five most common contact allergens were benzoic acid, methylisothiazolinone (MI), wood tar, nickel, and balsam of Peru. Allergic skin symptoms are present in all ages and also in the elderly. According to our data, the most common contact allergens are preservatives, followed by balsam of Peru among men and nickel among women. In case of contact dermatitis, stasis dermatitis, rosacea, and atopic dermatitis are worth patch testing to verify CH even in those above 60 years old.Entities:
Keywords: ageing; contact allergens; contact hypersensitivity; elderly
Year: 2022 PMID: 36013408 PMCID: PMC9410419 DOI: 10.3390/life12081228
Source DB: PubMed Journal: Life (Basel) ISSN: 2075-1729
European Environmental Baseline Series (EEBS) allergens (2015–2019).
| Allergen (Concentration) | Period | |
|---|---|---|
| 1. | Neomycin-sulphate (20%) | 2015- |
| 2. | Benzocaine (5%) | 2015- |
| 3. | Jodchlore-oxychinoline (clinoquinol) (5%) | 2015- |
| 4. | Paraben mix (16%) | 2015- |
| 5. | Lanoline alcohol (30%) | 2015- |
| 6. | Primin (0.01%) | 2015- |
| 7. | Sesquiterpen lactone (0.1 %) | 2015- |
| 8. | Phenylbutazone (10%) | 2015- |
| 9. | Potassium dichromate (0.5%) | 2015- |
| 10. | Nickel (II)-sulphate hexahydrate (5%) | 2015- |
| 11. | Cobalt (II)-chloride hexahydrate (1%) | 2015- |
| 12. | Thiuram mix (1%) | 2015- |
| 13. | 2-Mercaptobenzothiazole (MBT) (2%) | 2015- |
| 14. | Colophonium (20%) | 2015- |
| 15. | Wood tar (12%) | 2015- |
| 16. | Balsam of Peru ( | 2015- |
| 17. | Lyral® (Hidroxyisohexyl 3-cyclohexene carboxaldehyde) (5%) | 2018- |
| 18. | PPD (4-phenylendiamine base) (1%) | 2015- |
| 19. | Mercury (II)-amidochloride (1%) | 2015- |
| 20. | Formaldehyde (2%) | 2015- |
| 21. | 2015- | |
| 22. | Propylenglycol (20%) | 2015- |
| 23. | Thiomersal (0.1%) | 2015- |
| 24. | Quaternium 15 (Dowicil 200) (1%) | 2015- |
| 25. | Kathon CG® (methylchloroisothiazolinon/methylisothiazolinone (MCI/MI) 3:1) (0.01%) | 2015- |
| 26. | Resorcin (2%) | 2015- |
| 27. | Propolis (10%) | 2015- |
| 28. | 2015- | |
| 29. | Fragrance mix I (8%) | 2015- |
| 30. | Mercury-chloride (0.1%) | 2015- |
| 31. | Bisphenol A (epoxy resin) (1%) | 2015- |
| 32. | Budesonide (0.1%) | 2015- |
| 33. | Tixocortol-21-pivalate (1%) | 2015- |
| 34. | Methyldibromo-glutaronitrile (MDBGN) (0.3%) | 2015- |
| 35. | Fragrance mix II (14%) | 2015- |
| 36. | Lavender oil (2%) | 2015- |
| 37. | Methylisothiazolinone (MI) (0.2%) | 2015- |
| 38. | 2-hydroxyethyl-methacrylate (2%) | 2017- (98 patients in 2016) |
| 39. | Methyl-methacrylate (2%) | 2017- (98 patients in 2016) |
| 40. | Ethyl-acrylate (0.1%) | 2017- (98 patients in 2016) |
| 41. | Cocamidopropyl betaine (1%) | 2015- |
| 42. | d-Limonene (10%) | 24/10/2017- |
| 43. | Linalool (10%) | 24/10/2017- |
| 44. | Lauryl-glycoside (3%) | 2018- |
| 45. | Decyl-glycoside (5%) | 2018- |
| 46. | Sorbitan sesquioleate (20%) | 16/08/2019- |
| 47. | Turpentine oil (0.3%) | 2015–2017 |
| 48. | 19/02/2018- |
Complementary Fragrance Series (CFS) allergens (2015–2019).
| Allergen (Concentration) | Period | |
|---|---|---|
| 1. | Benzoic acid (5%) | 2015- |
| 2. | Cinnamon oil (0.5%) | 2015- |
| 3. | Vanilla (10%) | 2015- |
| 4. | Camphor (1%) | 2015- |
| 5. | Menthol (1%) | 2015- |
| 6. | Sorbic acid (2%) | 2015- |
Distribution of patients patch tested with EEBS (n = 600) and CFS (n = 440) according to gender and age (number of patients).
| EEBS | CFS | |||||
|---|---|---|---|---|---|---|
| Total | Male | Female | Total | Male | Female | |
|
| 348 | 72 | 276 | 262 | 50 | 212 |
|
| 210 | 46 | 164 | 147 | 33 | 114 |
|
| 42 | 10 | 32 | 31 | 6 | 25 |
|
| 600 | 128 | 472 | 440 | 89 | 351 |
Total >60-year-old patient population (n = 600) according to diagnosis and CH.
| Total >60 Years Patient Population ( | |||||
|---|---|---|---|---|---|
|
| Total (Number) | Total (%) | Patients with CH (Number) | Patients with CH (%) | Patients with CH (%) |
|
| 382 | 63.7 | 237 | 72.0 | 62.0 |
|
| 11 | 1.8 | 9 | 2.7 | 81.8 |
|
| 37 | 6.2 | 14 | 4.3 | 37.8 |
|
| 29 | 4.8 | 17 | 5.2 | 58.6 |
|
| 14 | 2.3 | 4 | 1.2 | 28.6 |
|
| 29 | 4.8 | 15 | 4.6 | 51.7 |
|
| 20 | 3.3 | 5 | 1.5 | 25.0 |
|
| 18 | 3.0 | 6 | 1.8 | 33.3 |
|
| 17 | 2.8 | 7 | 2.1 | 41.2 |
|
| 7 | 1.2 | 3 | 0.9 | 42.9 |
|
| 36 | 6.0 | 12 | 3.6 | 33.3 |
|
| 600 | 100.0 | 329 | 100.0 | 54.8 |
Other: M. Hailey-Hailey, prurigo, lichen planopilaris, lichen planus erosiva genitalis, vasculitis, bullous pemphigoid. Sézary syndrome, lichen sclerosis et atrophicus, observatio, prurigo nodalaris, mycosis fungoides, lichen ruber planus, parapsoriasis, granuloma annulare, progressive systemic sclerosis, pemphigus vulgaris.
Total (n = 600) and sensitised (n = 329) >60-year-old patient population according to diagnosis and gender.
| Total >60-Year-Old Patient Population ( | Sensitised >60-Year-Old Patient Population ( | |||||||
|---|---|---|---|---|---|---|---|---|
|
| Male | Male | Female | Female | Male | Male | Female | Female |
|
| 67 | 52.3 | 315 | 66.7 | 37 | 63.8 | 200 | 73.8 |
|
| 5 | 3.9 | 6 | 1.3 | 4 | 6.9 | 5 | 1.8 |
|
| 9 | 7.0 | 28 | 5.9 | 5 | 8.6 | 9 | 3.3 |
|
| 12 | 9.4 | 17 | 3.6 | 6 | 10.3 | 11 | 4.1 |
|
| 3 | 2.3 | 11 | 2.3 | 0 | 0.0 | 4 | 1.5 |
|
| 3 | 2.3 | 26 | 5.5 | 1 | 1.7 | 14 | 5.2 |
|
| 7 | 5.5 | 13 | 2.8 | 0 | 0.0 | 5 | 1.8 |
|
| 2 | 1.6 | 16 | 3.4 | 0 | 0.0 | 6 | 2.2 |
|
| 6 | 4.7 | 11 | 2.3 | 2 | 3.4 | 5 | 1.8 |
|
| 1 | 0.8 | 6 | 1.3 | 1 | 1.7 | 2 | 0.7 |
|
| 13 | 10.2 | 23 | 4.9 | 2 | 3.4 | 10 | 3.7 |
|
| 128 | 100.0 | 472 | 100.0 | 58 | 100.0 | 271 | 100.0 |
Other: M. Hailey-Hailey, prurigo, lichen planopilaris, lichen planus erosiva genitalis, vasculitis, bullous pemphigoid, Sézary syndrome, lichen sclerosus et atrophicus, observatio, prurigo nodalaris, mycosis fungoides, lichen ruber planus, parapsoriasis, granuloma annulare, progressive systemic sclerosis, pemphigus vulgaris.
Total (n = 600) and sensitised (n = 329) >60-year-old patient population according to diagnosis and age groups.
| Total >60-Year-Old Patient Population ( | Sensitised >60-Year-Old Patient Population ( | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 60–69 | 70–79 | >80 Years | 60–69 | 70–79 | >80 Years | |||||||
|
| Number | % | Number | % | Number | % | Number | % | Number | % | Number | % |
|
| 227 | 65.2 | 132 | 62.9 | 23 | 54.8 | 144 | 72.0 | 80 | 75.5 | 13 | 56.5 |
|
| 6 | 1.7 | 4 | 1.9 | 1 | 2.4 | 5 | 2.5 | 3 | 2.8 | 1 | 4.3 |
|
| 23 | 6.6 | 10 | 4.8 | 4 | 9.5 | 9 | 4.5 | 3 | 2.8 | 2 | 8.7 |
|
| 14 | 4.0 | 9 | 4.3 | 6 | 14.3 | 10 | 5.0 | 3 | 2.8 | 4 | 17.4 |
|
| 9 | 2.6 | 4 | 1.9 | 1 | 2.4 | 3 | 1.5 | 0 | 0.0 | 1 | 4.3 |
|
| 18 | 5.2 | 11 | 5.2 | 0 | 0.0 | 10 | 5.0 | 5 | 4.7 | 0 | 0.0 |
|
| 7 | 2.0 | 11 | 5.2 | 2 | 4.8 | 3 | 1.5 | 2 | 1.9 | 0 | 0.0 |
|
| 15 | 4.3 | 2 | 1.0 | 1 | 2.4 | 5 | 2.5 | 1 | 0.9 | 0 | 0.0 |
|
| 6 | 1.7 | 9 | 4.3 | 2 | 4.8 | 4 | 2.0 | 3 | 2.8 | 0 | 0.0 |
|
| 5 | 1.4 | 2 | 1.0 | 0 | 0.0 | 3 | 1.5 | 0 | 0.0 | 0 | 0.0 |
|
| 18 | 5.2 | 16 | 7.6 | 2 | 4.8 | 4 | 2.0 | 6 | 5.7 | 2 | 8.7 |
|
| 348 | 100.0 | 210 | 100.0 | 42 | 100.0 | 200 | 100.0 | 106 | 100.0 | 23 | 100.0 |
Other: M. Hailey-Hailey, prurigo, lichen planopilaris, lichen planus erosiva genitalis, vasculitis, bullous pemphigoid, Sézary syndrome, lichen sclerosus et atrophicus, observatio, prurigo nodalaris, mycosis fungoides, lichen ruber planus, parapsoriasis, granuloma annulare, progressive systemic sclerosis, pemphigus vulgaris.
Sensitised >60-year-old patient population (n = 329) according to clinical symptom localisation.
| Sensitised >60-Year-Old Patient Population ( | ||||
|---|---|---|---|---|
|
| Total | 60–69 | 70–79 | >80 Years |
|
| 32.5 | 35.0 | 29.2 | 26.1 |
|
| 31.9 | 34.5 | 28.3 | 26.1 |
|
| 18.5 | 19.5 | 16.0 | 21.7 |
|
| 21.0 | 21.5 | 20.8 | 17.4 |
|
| 50.5 | 50.0 | 52.8 | 43.5 |
|
| 45.6 | 41.0 | 51.9 | 56.5 |
|
| 26.4 | 24.0 | 30.2 | 30.4 |
|
| 19.8 | 17.5 | 21.7 | 30.4 |
|
| 23.1 | 23.0 | 23.6 | 21.7 |
|
| 14.9 | 15.0 | 14.2 | 17.4 |
Most common contact allergens of the sensitised >60-year-old patient population (n = 329) by gender.
| Sensitised >60-Year-Old Patient Population ( | |||||||
|---|---|---|---|---|---|---|---|
| Total ( | Male ( | Female ( | |||||
| Allergen | Number | % | Number | % | Number | % | |
|
|
| 71 | 16.1 | 16 | 18.0 | 55 | 15.7 |
|
|
| 79 | 13.2 | 16 | 12.5 | 63 | 13.3 |
|
|
| 65 | 10.8 | 10 | 7.8 | 55 | 11.7 |
|
|
| 64 | 10.7 | 4 | 3.1 | 60 | 12.7 |
|
|
| 58 | 9.7 | 18 | 14.1 | 40 | 8.5 |
|
|
| 49 | 8.2 | 12 | 9.4 | 37 | 7.8 |
|
|
| 40 | 6.7 | 12 | 9.4 | 28 | 5.9 |
|
|
| 39 | 6.5 | 6 | 4.7 | 33 | 7.0 |
|
|
| 34 | 5.7 | 5 | 3.9 | 29 | 6.1 |
|
|
| 33 | 5.5 | 11 | 8.6 | 22 | 4.7 |
|
|
| 22 | 5.0 | 4 | 4.5 | 18 | 5.1 |
|
|
| 25 | 4.2 | 4 | 3.1 | 21 | 4.4 |
|
| 25 | 4.2 | 2 | 1.6 | 23 | 4.9 | |
|
| 25 | 4.2 | 4 | 3.1 | 21 | 4.4 | |
|
|
| 18 | 3.0 | 1 | 0.8 | 17 | 3.6 |
|
|
| 17 | 2.8 | 1 | 0.8 | 16 | 3.4 |
|
|
| 16 | 2.7 | 2 | 1.6 | 14 | 3.0 |
|
|
| 14 | 2.3 | 1 | 0.8 | 13 | 2.8 |
|
|
| 12 | 2.0 | 3 | 2.3 | 9 | 1.9 |
|
| 12 | 2.0 | 3 | 2.3 | 9 | 1.9 | |
|
|
| 11 | 1.8 | 5 | 3.9 | 6 | 1.3 |
|
| 11 | 1.8 | 5 | 3.9 | 6 | 1.3 | |
|
| 11 | 1.8 | 0 | 0.0 | 11 | 2.3 | |
|
|
| 10 | 1.7 | 4 | 3.1 | 6 | 1.3 |
|
|
| 9 | 1.5 | 1 | 0.8 | 8 | 1.7 |
|
| 9 | 1.5 | 1 | 0.8 | 8 | 1.7 | |
Data of Table 3 were used for calculating: for complementary fragrance series allergens, the total population consisted of 440 patients.
Most common contact allergens of the sensitised 60–69-year-old patient population (n = 200) by gender.
| Sensitised 60–69-Year-Old Patients ( | |||||||
|---|---|---|---|---|---|---|---|
| Total ( | Male ( | Female ( | |||||
| Allergen | Number | % | Number | % | Number | % | |
|
|
| 40 | 15.3 | 6 | 12.0 | 34 | 16.0 |
|
|
| 47 | 13.5 | 10 | 13.9 | 37 | 13.4 |
|
|
| 46 | 13.2 | 2 | 2.8 | 44 | 15.9 |
|
|
| 38 | 10.9 | 4 | 5.6 | 34 | 12.3 |
|
|
| 34 | 9.8 | 10 | 13.9 | 24 | 8.7 |
|
|
| 29 | 8.3 | 5 | 6.9 | 24 | 8.7 |
|
|
| 21 | 6.0 | 3 | 4.2 | 18 | 6.5 |
|
| 21 | 6.0 | 7 | 9.7 | 14 | 5.1 | |
|
|
| 20 | 5.7 | 4 | 5.6 | 16 | 5.8 |
|
| 20 | 5.7 | 8 | 11.1 | 12 | 4.3 | |
|
|
| 16 | 4.6 | 2 | 2.8 | 14 | 5.1 |
|
| 12 | 4.6 | 2 | 4.0 | 10 | 4.7 | |
|
|
| 14 | 4.0 | 1 | 1.4 | 13 | 4.7 |
|
| 14 | 4.0 | 3 | 4.2 | 11 | 4.0 | |
Data of Table 3 were used for calculating: for complementary fragrance series allergens, the total population consisted of 440 patients.
Most common contact allergens of the sensitised 70–79-year-old patient population (n = 106) by gender.
| Sensitised 70–79-Year-Old Patients ( | |||||||
|---|---|---|---|---|---|---|---|
| Total ( | Male ( | Female ( | |||||
| Allergen | Number | % | Number | % | Number | % | |
|
|
| 24 | 16.3 | 9 | 27.3 | 15 | 13.2 |
|
|
| 30 | 14.3 | 6 | 13.0 | 24 | 14.6 |
|
|
| 20 | 9.5 | 5 | 10.9 | 15 | 9.1 |
|
|
| 18 | 8.6 | 7 | 15.2 | 11 | 6.7 |
|
|
| 17 | 8.1 | 2 | 4.3 | 15 | 9.1 |
|
|
| 16 | 7.6 | 5 | 10.9 | 11 | 6.7 |
|
|
| 15 | 7.1 | 7 | 15.2 | 8 | 4.9 |
|
|
| 14 | 6.7 | 2 | 4.3 | 12 | 7.3 |
|
|
| 13 | 6.2 | 1 | 2.2 | 12 | 7.3 |
|
|
| 9 | 6.1 | 2 | 6.1 | 7 | 6.1 |
Data of Table 3 were used for calculating: for complementary fragrance series allergens, the total population consisted of 440 patients.
Most common contact allergens of the sensitised >80-year-old patient population (n = 23) by gender.
| Sensitised >80-Year-Old Patients ( | |||||||
|---|---|---|---|---|---|---|---|
| Total ( | Male ( | Female ( | |||||
| Allergen | Number | % | Number | % | Number | % | |
|
|
| 7 | 22.6 | 1 | 16.7 | 6 | 24.0 |
|
|
| 7 | 16.7 | 1 | 10.0 | 6 | 18.8 |
|
|
| 6 | 14.3 | 1 | 10.0 | 5 | 15.6 |
|
|
| 5 | 11.9 | 0 | 0.0 | 5 | 15.6 |
|
|
| 4 | 9.5 | 1 | 10.0 | 3 | 9.4 |
|
|
| 3 | 7.1 | 1 | 10.0 | 2 | 6.3 |
|
| 3 | 7.1 | 0 | 0.0 | 3 | 9.4 | |
|
|
| 2 | 4.8 | 0 | 0.0 | 2 | 6.3 |
|
| 2 | 4.8 | 1 | 10.0 | 1 | 3.1 | |
|
| 2 | 4.8 | 0 | 0.0 | 2 | 6.3 | |
|
| 2 | 4.8 | 0 | 0.0 | 2 | 6.3 | |
|
|
| 1 | 3.2 | 0 | 0.0 | 1 | 4.0 |
|
| 1 | 3.2 | 0 | 0.0 | 1 | 4.0 | |
|
| 1 | 3.2 | 0 | 0.0 | 1 | 4.0 | |
|
|
| 1 | 2.4 | 0 | 0.0 | 1 | 3.1 |
|
| 1 | 2.4 | 0 | 0.0 | 1 | 3.1 | |
|
| 1 | 2.4 | 0 | 0.0 | 1 | 3.1 | |
|
| 1 | 2.4 | 0 | 0.0 | 1 | 3.1 | |
|
| 1 | 2.4 | 0 | 0.0 | 1 | 3.1 | |
|
| 1 | 2.4 | 0 | 0.0 | 1 | 3.1 | |
|
| 1 | 2.4 | 1 | 10.0 | 0 | 0.0 | |
|
| 1 | 2.4 | 0 | 0.0 | 1 | 3.1 | |
|
| 1 | 2.4 | 0 | 0.0 | 1 | 3.1 | |
|
| 1 | 2.4 | 0 | 0.0 | 1 | 3.1 | |
|
| 1 | 2.4 | 0 | 0.0 | 1 | 3.1 | |
Data of Table 3 were used for calculating: for complementary fragrance series allergens, the total population consisted of 440 patients.